Cell and Gene Therapy Contract Research Organization Market Report 2026

The cell and gene therapy contract research organization market size has grown rapidly in recent years. It will grow from $6.92 billion in 2025 to $7.76 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to increasing number of early-stage cell and gene therapy programs, limited in-house development capabilities, growth in rare disease research pipelines, rising regulatory complexity in advanced therapies, increasing reliance on external research expertise.

The cell and gene therapy contract research organization market size is expected to see rapid growth in the next few years. It will grow to $12.36 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing clinical trial activity in gene therapies, expansion of personalized medicine development, rising investments in oncology and genetic disorder research, growing demand for accelerated development timelines, increasing collaboration between biotech firms and CROs. Major trends in the forecast period include increasing outsourcing of cell and gene therapy research, rising demand for integrated preclinical and clinical services, growing focus on regulatory and compliance expertise, expansion of vector development and manufacturing support, enhanced use of data-driven trial management.

The rising focus on personalized medicine and targeted therapeutics is expected to propel the growth of the cell and gene therapy contract research organization (CRO) market going forward. Personalized medicine and targeted therapeutics involve the development of treatments tailored to individual genetic, molecular, or cellular characteristics to improve efficacy and reduce adverse effects. The focus on personalized medicine is increasing as regulators and healthcare systems prioritize precision-based therapies to address complex diseases and achieve higher clinical success rates. Cell and gene therapy contract research organizations (CROs) support personalized medicine by providing specialized preclinical, clinical, and regulatory services required to develop, test, and validate complex gene- and cell-based therapeutic products. For instance, in April 2025, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the Food and Drug Administration (FDA) approved 18 personalized medicines in 2024, accounting for approximately 38% of all newly approved therapeutic molecular entities. Therefore, the rising focus on personalized medicine and targeted therapeutics is driving the growth of the cell and gene therapy contract research organization (CRO) market.

Leading companies operating in the cell and gene therapy contract research organization (CRO) market are focusing on developing innovative solutions, such as expanded laboratory and analytical services, to improve therapy development efficiency, regulatory compliance, and research precision by offering state-of-the-art facilities, specialized equipment, and integrated cell and gene therapy testing capabilities. Expanded laboratory and analytical services refer to contract research organization (CRO) offerings that increase operational capacity, enable complex assay execution, and support sponsors with end-to-end development of advanced cell and gene therapies. For example, in August 2025, Labcorp Holdings Inc., a US-based healthcare company, expanded its cell and gene therapy laboratory in Madison, Wisconsin, strengthening its capabilities for cell characterization, vector analytics, and regulatory-compliant testing. The expanded facility delivers specialized infrastructure for complex cell and gene therapy workflows, supports high-throughput sample processing, and integrates advanced analytical platforms, positioning it as a comprehensive solution for accelerating cell and gene therapy research and development.

In January 2023, Novotech Clinical Research, a Singapore-based full-service contract research organization (CRO), acquired EastHORN Clinical Services for an undisclosed amount. Through this acquisition, Novotech aims to enhance its global operations by integrating EastHORN’s clinical, medical, and regulatory expertise across Europe, enabling seamless delivery of early- to late-phase clinical development services for biotech clients. EastHORN Clinical Services is a Poland-based contract research organization (CRO) that offers clinical, medical, and regulatory support for cell and gene therapy development within global clinical trial programs.

Major companies operating in the cell and gene therapy contract research organization market are Thermo Fisher Scientific Inc., IQVIA Holdings Inc., Laboratory Corporation of America Holdings (Labcorp), ICON plc, WuXi AppTec Co. Ltd., Syneos Health Inc., Charles River Laboratories International Inc., Parexel International Corporation, Fortrea Holdings Inc., CMIC Co. Ltd., Medpace Holdings Inc., PharmaLex GmbH, Premier Research International LLC, Worldwide Clinical Trials Inc., Novotech (Australia) Pty Ltd., Precision for Medicine Inc., Syngene International Limited, Allucent Inc., TFS HealthScience AB, QPS Holdings LLC, Altasciences Company Inc., Veristat LLC, Linical Co. Ltd., Aixial Group, ProRelix Research LLC.

Tariffs are impacting the cell and gene therapy contract research organization market by increasing costs of imported laboratory instruments, bioreactors, viral vector components, analytical equipment, and consumables used in advanced therapy research. North America and Europe are most affected due to reliance on imported high-end research tools, while Asia-Pacific faces cost pressures in CRO service expansion. These tariffs are raising operational expenses and project costs for sponsors. However, they are also encouraging regional capacity building, localized laboratory infrastructure development, and increased investment in domestic advanced therapy research ecosystems.

The cell and gene therapy contract research organization market research report is one of a series of new reports that provides cell and gene therapy contract research organization market statistics, including cell and gene therapy contract research organization industry global market size, regional shares, competitors with a cell and gene therapy contract research organization market share, detailed cell and gene therapy contract research organization market segments, market trends and opportunities, and any further data you may need to thrive in the cell and gene therapy contract research organization industry. This cell and gene therapy contract research organization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A cell and gene therapy contract research organization is a specialized external research provider that delivers end-to-end research and development services for advanced cell-based and gene-based therapeutic products. These organizations support both preclinical and clinical phases by supplying scientific knowledge, regulatory guidance, and study coordination tailored to the complexities of biological therapies. They help developers speed up innovation, lower development risks, and achieve smoother advancement from early research through clinical assessment.

The primary types of cell and gene therapy contract research organizations (CROs) include preclinical contract research organizations, clinical-stage contract research organizations, and other types. Preclinical contract research organizations provide laboratory and animal model studies to evaluate the safety and efficacy of cell and gene therapies before human clinical trials. These organizations offer services such as project and clinical trial management, regulatory strategy, data management and medical writing, clinical monitoring, quality management and good manufacturing practice compliance, biostatistics and safety monitoring, patient and site recruitment, technology transfer, and other services. They support therapeutic indications including oncology, central nervous system disorders, infectious diseases, immunological disorders, cardiovascular diseases, respiratory diseases, diabetes, ophthalmology, pain management, and other indications. They are applied across modalities such as cell-based therapies, gene therapies, and gene-modified cell therapies, and are utilized in applications including hospitals, research institutes, and other facilities.

The cell and gene therapy contract research organization market includes revenues earned by entities through preclinical research services, clinical trial management, vector development and manufacturing support, regulatory and compliance services, and bioanalytical and biomarker testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.